TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer

Name: TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer
Published: 2025
License: Public Domain

First Hospital of China Medical University · 2025

ClinicalTrials.gov · Datasets · License: Public Domain · 2025

Open Source ↗

triple-negative-breast-cancer

tnbc, triple negative breast cancer, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer

Related documents